KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 21];9(6):s712. Available from: https://skin.dermsquared.com/skin/article/view/3898